Monitoring the Response of Chemotherapy on Breast Cancer Tumor by Photon Migration Spectroscopy

Optimal management of patients with locally advanced breast cancer remains a complex therapeutic problem. Newly diagnosed breast cancers in the United States with a higher incidence in medically underserved areas. The optimal intensity and duration of neoadjuvant chemotherapy still remains controversial due to the difficulty of evaluating response to therapy. The goal would be to prevent over and under treatment of patients with neoadjuvant chemotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

21 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Beckman Laser Institute University Of California Irvine, Irvine, California, United States

About this study

The Researcher developed a diagnostic device called Diffuse Optical Spectroscopy Imaging is a non-invasive optical technique that utilizes intensity-modulated, near-infrared light to quantitatively measure optical properties in thick tissues.

Diffuse Optical Spectroscopy Imaging can images tissue hemoglobin , oxygen saturation, blood volume fraction, water content, fat content and cellular structure. The measurements provide quantitative optical property values that reflect changes in tissue perfusion, oxygen consumption, and cell/matrix development.

There is no therapeutic benefit to the subject, especially none that might influence the indication for the diagnostic procedure as indicated. However, information obtained may lead to a new form of non-invasive imaging for the early detection of breast cancer.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Female non-pregnant and age greater than or equal to 21 years old but less than 75 years old
Diagnosed with breast cancer and will be receiving neoadjuvant chemotherapy

Exclusion criteria

Female pregnant and age less than 21 years old and have no diagnosis of breast cancer

Treatment and study plan

Diffuse Optical Spectroscopy Imaging

Device

Diffuse Optical Spectroscopy Imaging

Primary outcomes

Diagnostic tool

Time frame: 12 weeks

Diffuse Optical Spectroscopy Imaging Breast Cancer Tumor in the response of Chemotherapy

Sponsors and collaborators

Lead sponsor

University of California, Irvine

Other

Collaborators

Beckman Laser Institute University of California Irvine
Chao Family Comprehensive Cancer Center

Registry information

Important dates

Study start: 2002
Primary completion: 2011
Study completion: 2011
First posted: Oct 8, 2007
Registry last updated: Nov 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed